Show simple item record

dc.contributor.authorYoon, Byung-Ho
dc.contributor.authorJones, Lynne C
dc.contributor.authorChen, Chung-Hwan
dc.contributor.authorCheng, Edward Y
dc.contributor.authorCui, Quanjun
dc.contributor.authorDrescher, Wolf
dc.contributor.authorFukushima, Wakaba
dc.contributor.authorGangji, Valerie
dc.contributor.authorGoodman, Stuart B
dc.contributor.authorHa, Yong-Chan
dc.contributor.authorHernigou, Philippe
dc.contributor.authorHungerford, Marc
dc.contributor.authorIorio, Richard
dc.contributor.authorJo, Woo-Lam
dc.contributor.authorKhanduja, Vikas
dc.contributor.authorKim, Harry
dc.contributor.authorKim, Shin-Yoon
dc.contributor.authorKim, Tae-Young
dc.contributor.authorLee, Hee Young
dc.contributor.authorLee, Mel S
dc.contributor.authorLee, Young-Kyun
dc.contributor.authorLee, Yun Jong
dc.contributor.authorMont, Michael A
dc.contributor.authorSakai, Takashi
dc.contributor.authorSugano, Nobuhiko
dc.contributor.authorTakao, Masaki
dc.contributor.authorYamamoto, Takuaki
dc.contributor.authorKoo, Kyung-Hoi
dc.date.accessioned2019-05-06T23:30:24Z
dc.date.available2019-05-06T23:30:24Z
dc.date.issued2019-01
dc.identifier.issn0883-5403
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/292432
dc.description.abstractBACKGROUND: Glucocorticoid usage, a leading cause of osteonecrosis of the femoral head (ONFH), and its prevalence was reported in 25%-50% of non-traumatic ONFH patients. Nevertheless, there have been no unified criteria to classify glucocorticoid-associated ONFH (GA-ONFH). In 2015, the Association Research Circulation Osseous addressed the issue of developing a classification scheme. METHODS: In June 2017, a task force was set up to conduct a Delphi survey concerning ONFH. The task force invited 28 experts in osteonecrosis/bone circulation from 8 countries. Each round of the Delphi survey consists of questionnaires, analysis of replies, and feedback reports to the panel. After 3 rounds of the survey, the panel reached a consensus on the classification criteria. The response rates were 100% (Round 1), 96% (Round 2), and 100% (Round 3), respectively. RESULTS: The consensus on the classification criteria of GA-ONFH included the following: (1) patients should have a history of glucocorticoid use >2 g of prednisolone or its equivalent within a 3-month period; (2) osteonecrosis should be diagnosed within 2 years after glucocorticoid usage, and (3) patients should not have other risk factor(s) besides glucocorticoids. CONCLUSION: Association Research Circulation Osseous established classification criteria to standardize clinical studies concerning GA-ONFH.
dc.format.mediumPrint-Electronic
dc.languageeng
dc.publisherElsevier BV
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHumans
dc.subjectFemur Head Necrosis
dc.subjectPrednisolone
dc.subjectGlucocorticoids
dc.subjectRisk Factors
dc.subjectConsensus
dc.subjectInternationality
dc.subjectDelphi Technique
dc.subjectAdvisory Committees
dc.titleEtiologic Classification Criteria of ARCO on Femoral Head Osteonecrosis Part 1: Glucocorticoid-Associated Osteonecrosis.
dc.typeArticle
prism.endingPage168.e1
prism.issueIdentifier1
prism.publicationDate2019
prism.publicationNameJ Arthroplasty
prism.startingPage163
prism.volume34
dc.identifier.doi10.17863/CAM.39589
dcterms.dateAccepted2018-09-10
rioxxterms.versionofrecord10.1016/j.arth.2018.09.005
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2019-01
dc.contributor.orcidKhanduja, Vikas [0000-0001-9454-3978]
dc.identifier.eissn1532-8406
rioxxterms.typeJournal Article/Review
cam.orpheus.successThu Jan 30 10:47:43 GMT 2020 - Embargo updated
rioxxterms.freetoread.startdate2020-01-31


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International